Frontiers in Endocrinology最新文献

{"title":"Single-nucleus RNA sequencing reveals dynamic changes in the microenvironment of visceral adipose tissue and metabolic characteristics after cold exposure.","authors":"Ting Yi, Shuai Wu, Yusha Yang, Xi Li, Shuran Yang, Yongqiang Zhang, Li Zhang, Yuyu Hu, Guanyu Zhang, Jun Li, Danfeng Yang","doi":"10.3389/fendo.2025.1562431","DOIUrl":"10.3389/fendo.2025.1562431","url":null,"abstract":"<p><strong>Introduction: </strong>Visceral adipose tissue (VAT) plays a crucial role in regulating systemic metabolic balance. Excess accumulation of VAT is closely associated with various metabolic disorders, a process that involves the coordinated actions of multiple cell types within the tissue. Cold exposure, as a potential intervention, has been proposed to improve metabolic dysfunction. However, the heterogeneity of VAT and its comprehensive metabolic characteristics under cold exposure remain unclear.</p><p><strong>Methods: </strong>We collected epididymal white adipose tissue (eWAT) of C57BL/6J mice after cold exposure at three different time points for single-nucleus RNA sequencing (snRNA-seq) analysis.</p><p><strong>Results: </strong>We successfully identified ten major cell types in eWAT, enabling understanding of the dynamic changes in the eWAT microenvironment and its metabolic features during cold exposure. This study revealed that cold exposure for 1 day reduced cellular metabolic activity and intercellular communication in eWAT including receptor-ligand-based cell communication and metabolite-mediated interactions. However, after 14 days of cold acclimation, the metabolic activity of adipocytes was significantly enhanced, and intercellular metabolic communication was restored. Additionally, prolonged cold exposure promoted the formation of a distinct adipocyte subpopulation that may be associated with UCP1-independent thermogenesis. These changes may be a new homeostatic state established by VAT to adapt to the cold environment. The study also identified the importance of adipocytes, adipose stem and progenitor cells, myeloid cells, and endothelial cells in the process of cold adaptation.</p><p><strong>Discussion: </strong>This research provides valuable insights into the cellular heterogeneity, adipocyte remodeling, and metabolic reprogramming in eWAT after cold exposure. It highlights the critical role of transcriptional dynamics in eWAT during cold exposure and provides new perspectives on the prevention and treatment of metabolic diseases.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1562431"},"PeriodicalIF":3.9,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between smoking and osteoporosis and all-cause mortality in participants from the United States: a cohort study.","authors":"Xiaoqin Qu, Jingcheng Jiang, Qingshan Deng, Han Wang, Chao Zhang, Xiaoping Xu, Yong Yi, Lihua Qiu","doi":"10.3389/fendo.2025.1533633","DOIUrl":"10.3389/fendo.2025.1533633","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Smoking is a global public health concern, with approximately 1,245 billion smokers worldwide. It is associated with a range of health complications, including cardiovascular and respiratory diseases. Osteoporosis, characterized by reduced bone density and deterioration of bone tissue, has a global prevalence of 18.3%, with higher rates in women over the age of 50. Smoking has been recently associated with osteoporosis, potentially due to shared metabolic disorders or personal habits. This study aimed to investigate the association between smoking and osteoporosis in relation to all-cause mortality in a cohort from the United States.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Data were sourced from the National Health and Nutrition Examination Survey (NHANES) database, which focuses on individuals aged 20 years and older from 2005-2010, 2013-2014, and 2017-2018, where femoral neck bone density testing was conducted. The participants were categorized on the basis of their self-reported smoking status and bone mineral density (BMD) measurements, following the World Health Organization criteria for osteoporosis. The covariates included age, sex, race, alcohol consumption, BMI, blood glucose levels, and other health indicators. Statistical analysis included ANOVA and chi-square tests for baseline characteristics, Kaplan-Meier survival analysis, and multivariate Cox regression analysis to assess hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality. We divided the patients into four different groups via a cross-classification method on the basis of smoking status and whether they had osteoporosis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;This study included 19,400 participants, with significant differences in baseline characteristics across 4 groups (S-/OP+: nonsmokers with osteoporosis; S+/OP-: smokers without osteoporosis; S-/OP-: nonsmokers without osteoporosis; S+/OP+: smokers with osteoporosis). The overall average age was 53.1 years, and women accounted for 49.6% of the total population. The mortality rate due to all factors in the total population was 13.1%, with the highest S+/OP+ mortality rate. Participants with both a smoking history and osteoporosis had a 146% increase in all-cause mortality (HR: 2.46, 95% CI: 2.12-2.87) even after adjusting for confounding factors. The relative excess risk due to interaction (RERI) suggested a lack of statistical significance, whereas the attributable proportion (AP) indicated a synergistic effect between smoking and osteoporosis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;This cohort study highlights the importance of managing and preventing smoking and osteoporosis to reduce the risk of all-cause mortality. The findings provide preliminary evidence of a synergistic effect between smoking and osteoporosis on all-cause mortality risk, emphasizing the need for proactive strategies for smoking cessation and close monitoring of risk factors in individuals with both conditions.&lt;/","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1533633"},"PeriodicalIF":3.9,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Animal models in the study of diabetic erectile dysfunction: mechanisms and applications.","authors":"Xin Zhang, Yihao Chen, Jiahua Qian, Yuhe Si, Chenxi Wang, Jingwei Wang, Qiang He, Jianxiong Ma","doi":"10.3389/fendo.2025.1512360","DOIUrl":"10.3389/fendo.2025.1512360","url":null,"abstract":"<p><strong>Background: </strong>Diabetic erectile dysfunction (DMED) is a common complication of diabetes. While research on DMED relies primarily on animal models, replicating the intricate etiology and multi-system interactions of human DMED in a single model remains a challenge.</p><p><strong>Aim: </strong>This article provides a comprehensive overview of animal models used in DMED research and emphasizes the crucial role they play in understanding the pathogenesis and treatment of DMED.</p><p><strong>Methods: </strong>A comprehensive medical literature was searched in PubMed and Medline, focusing on original studies and systematic reviews of original studies involving animal models of diabetic erectile dysfunction. Clinical studies, editorials, letters, reviews, and non-English articles were excluded.</p><p><strong>Results: </strong>This article compiles various animal models currently used in the study of diabetes and diabetic erectile dysfunction (DMED), with a particular emphasis on the application of rodent models such as rats and mice. These animals demonstrate significant advantages in terms of economy, practicality, and reproducibility in DMED research and share similarities with humans in tissue morphology and functional characteristics.</p><p><strong>Conclusion: </strong>This manuscript offers researchers multiple insights into selecting animal models for DMED, particularly considering their practicality, cost-effectiveness, and reproducibility. The integrated information serves as a valuable reference for researchers in choosing suitable models.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1512360"},"PeriodicalIF":3.9,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of eleven Chinese patent medicines combined with atorvastatin in the treatment of hyperlipidemia: a network meta-analysis of randomized controlled trials.","authors":"Zeyang Shi, Wei Zheng, Zhijun Bu, Xian Zhou, Xuefeng Wang, Yike Song, Jialin Sun, Jian-Ping Liu, Zhao-Lan Liu","doi":"10.3389/fendo.2025.1523553","DOIUrl":"10.3389/fendo.2025.1523553","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Randomized controlled trials (RCTs) suggested that combining Chinese patent medicines with atorvastatin exhibited superior effectiveness in treating hyperlipidemia with reduced adverse reactions. However, the evidence regarding the clinical effectiveness and safety was not assessed to make informed decision in clinical practice.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate the clinical effectiveness and safety of combined Chinese patent medicines with atorvastatin.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Eight databases (CNKI, Wanfang, VIP, SinoMed, PubMed, Embase, Web of Science, and Cochrane Library) were searched from inception to April 2024. The risk of bias (ROB) of the included RCTs was assessed using the ROB 2.0 tool recommended by the Cochrane Handbook. The surface under the cumulative ranking curve (SUCRA) probability values were used to rank the treatment measures, and the Confidence in Network Meta-Analysis (CINeMA) software was used to assess the grading of evidence.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 23 RCTs involving 2184 patients with hyperlipidemia were included. Hedan (tablets or capsules) combined with atorvastatin showed the highest clinical effectiveness with an RR of 1.58 (95% CI: [1.14, 2.12]) (SUCRA: 80.36%), the lowest post-treatment low-density lipoprotein cholesterol (LDL-C) level with an MD of -8.13(95% CI: [-9.70, -6.57]) (SUCRA: 3.37%), and the lowest post-treatment triglyceride (TG) level with an MD of -6.43(95% CI: [-7.71, -5.16]) (SUCRA: 0.33%). Dantian Jiangzhi Granules demonstrated the lowest post-treatment total cholesterol (TC) level with an MD of -2.22(95% CI: [-2.60, -1.83]) (SUCRA: 12.6%), while Xuezhikang Capsules displayed the highest post-treatment high-density lipoprotein cholesterol (HDL-C) level with an MD of 1.61(95% CI: [0.82, 2.39]) (SUCRA: 79.87%). However, it is important to note that most of the included studies showed \"some concerns\" regarding the risk of bias based on ROB 2.0. According to CINeMA, most confidence rating results were classified as \"low\".&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Compared to atorvastatin alone, the combination of Chinese patent medicines with atorvastatin demonstrated superior effectiveness in treating hyperlipidemia. Among these, Hedan (tablets or capsules) exhibited the greatest overall benefit, significantly reducing TG and LDL-C levels. Dantian Jiangzhi Granules had the most pronounced effect in lowering TC, while Xuezhikang was most effective in improving HDL-C level. Although Xuezhikang is well-documented as lipid-lowering agent, the findings of this study suggest that hyperlipidemia treatment should be tailored to individual blood lipid profiles. Additionally, for drugs with limited evidence of efficacy and safety, larger randomized controlled trials and further pharmacological studies are necessary to valid these results.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Systematic review registration: &lt;/strong&gt;https://www.crd.york.ac.uk/prospero/, identifier CRD42","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1523553"},"PeriodicalIF":3.9,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver function differences in atherosclerotic cardiovascular disease: a multi-ethnic dual-cohort retrospective study.","authors":"Yifei Wang, Zichen Zhang, Wenbo Ren, Lin Shi, Taiyu Zhai, Jing Huang","doi":"10.3389/fendo.2025.1558872","DOIUrl":"10.3389/fendo.2025.1558872","url":null,"abstract":"<p><strong>Background and aims: </strong>Liver function plays a pivotal role in the initiation and progression of atherosclerotic cardiovascular disease (ASCVD). Exploring the potential associations between liver function assessment indicators and ASCVD is essential for understanding the liver's involvement in ASCVD pathogenesis. However, the specific relationships between these indicators and ASCVD are still debated. This study aims to conduct an in-depth comparative analysis of variations in various liver function assessment indicators among populations of ASCVD patients.</p><p><strong>Methods: </strong>A dual-cohort retrospective cross-sectional study design was employed, using data from 15,943 ASCVD patients at the First Hospital of Jilin University and 472 ASCVD patients from the National Health and Nutrition Examination Survey (NHANES) database. Liver function indicators, including enzymatic, protein synthesis, bilirubin metabolism indices, and lipid profile parameters, were analyzed. Inclusion and exclusion criteria were rigorously applied, followed by univariate regression, multivariate regression and stratified subgroup analyses.</p><p><strong>Results: </strong>Hepatocyte damage indicators (aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, alkaline phosphatase) and total bilirubin were identified as risk factors for ASCVD. Albumin showed a protective effect. Globulin levels differed significantly between cohorts. Cholinesterase (cohort 1) and total protein, total cholesterol (cohort 2) showed no significant changes in ASCVD patients.</p><p><strong>Conclusion: </strong>Many liver function indicators are correlated with ASCVD. There are differences in these indicators between ASCVD patients and healthy volunteers. Although some indicators may be weakly correlated due to confounding factors, this study still provides a scientific rationale for developing more precise ASCVD prevention and treatment strategies in the future.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1558872"},"PeriodicalIF":3.9,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of administration routes on the efficacy of human umbilical cord mesenchymal stem cells in type 2 diabetic rats.","authors":"Qiqiang Tao, Youzhi Wu, Huiwen Pang, Pinglei Lv, Wenrui Li, Xuqiang Nie, Felicity Y Han","doi":"10.3389/fendo.2025.1536655","DOIUrl":"10.3389/fendo.2025.1536655","url":null,"abstract":"<p><strong>Background: </strong>Human umbilical cord mesenchymal stem cells (UCMSCs) are being investigated in various clinical trials for different conditions, including type 2 diabetes mellitus (T2DM). However, there is limited research on the optimal injection routes for UCMSCs in T2DM, particularly intravenous injection.</p><p><strong>Objective: </strong>The objective of this study aims to investigate the efficacy of four different administration routes of UCMSCs in treating T2DM rats, including pancreas injection (DP), tail vein injection (DT), intraperitoneal injection (DI), and dorsal pancreatic artery injection (DPA).</p><p><strong>Results: </strong>After two weeks of UCMSCs treatment, the fasting blood glucose levels in the DT group decreased significantly. The oral glucose tolerance test (OGTT) levels and the islet structure in the DT group almost recovered to normal. The contents of C-P and GLP-1 in serum increased significantly in all treatment groups, while the levels of INS, TNF-α, IL-6, IL-1β, IAA, and GSP decreased significantly. These improvements were further observed after four weeks of UCMSCs treatment. Histological analysis confirmed the progression of pancreatic recovery in all treatment groups, with the DT group showing the most significant improvement, correlating with the observed efficacy. Immunohistochemistry results further demonstrated increased insulin and PDX-1 expression, along with reduced glucagon levels in UCMSCs-treated rats. Additionally, liver and kidney function significantly improved across all treatment groups, with the DT group showing the best outcomes.</p><p><strong>Conclusion: </strong>Overall, these findings suggest that the administration route significantly affected the efficacy of UCMSCs in treating T2DM, with tail vein injection showing the most effective results.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1536655"},"PeriodicalIF":3.9,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The non-linear relationship between the visceral adiposity index and the risk of prediabetes and diabetes.","authors":"Lan Huang, Jing Liao, Chunyan Lu, Yiqiong Yin, Yanling Ma, Yue Wen","doi":"10.3389/fendo.2025.1407873","DOIUrl":"10.3389/fendo.2025.1407873","url":null,"abstract":"<p><strong>Background: </strong>The visceral adiposity index is a valuable tool for assessing visceral fat accumulation. However, its non-linear association with prediabetes and diabetes requires further elucidation. Therefore, we aim to clarify the intricate interplay between the visceral adiposity index and these dysglycemic conditions.</p><p><strong>Methods: </strong>The National Health and Nutrition Examination Survey database from 1999 to 2018 was utilized to analyze health data from 24,072 participants. A multivariate logistic regression model was employed to evaluate the independent association between the visceral adiposity index and prediabetes and diabetes while considering potential confounding factors. Generalized additive models were used to identify any non-linear relationships by fitting smooth curves. Additionally, a stratified analysis based on different baseline characteristics was conducted, along with an interactive analysis.</p><p><strong>Results: </strong>After accounting for all relevant variables, individuals in the lowest quartile of the visceral adiposity index had a notably diminished likelihood of progressing to prediabetes and diabetes when compared with those in the other three quartiles. The odds ratios and 95% confidence intervals were as follows: 1.37 (1.23, 1.53), 1.87 (1.65, 2.12), and 2.80 (2.33, 3.37). More importantly, a non-linear association was observed between the visceral adiposity index and prediabetes and diabetes, with a threshold identified at 2.10.</p><p><strong>Conclusions: </strong>There exists a notable and positive association between the visceral adiposity index and prediabetes and diabetes, displaying non-linear attributes in this evaluation of the relationship. Risk assessment and early prevention strategies targeting the maintenance of low levels of visceral adiposity index may substantially diminish the likelihood of developing prediabetes and diabetes.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1407873"},"PeriodicalIF":3.9,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clomiphene citrate reduces premature LH surge in obese women during controlled ovarian stimulation: a retrospective cohort study.","authors":"Yuqi Zeng, Yuting Huang, Yali Liu, Xi Shen, Yunhan Nie, Li Wang, Yanping Kuang","doi":"10.3389/fendo.2025.1512821","DOIUrl":"10.3389/fendo.2025.1512821","url":null,"abstract":"<p><strong>Background: </strong>Clomiphene citrate effectively suppressed the negative feedback of estrogen on the hypothalamus and induces premature luteinizing hormone (LH) surge during controlled ovulation stimulation, while obese women often have impaired hypothalamic-pituitary function. This study aimed to investigate whether the utilization of clomiphene citrate for controlled ovulation stimulation in obese women can effectively decrease the likelihood of premature LH surge.</p><p><strong>Methods: </strong>A retrospective study was conducted on women under the age of 38 with normal menstrual cycles and ovarian reserve who underwent controlled ovulation stimulation (COH) using clomiphene citrate. The participants were categorized by the Asian body mass index (BMI) classification. The dynamic reproductive endocrinological profiles during COH, especially the probability of serum LH concentration exceeding 10 IU/L, as well as the outcomes related to the embryo development and pregnancy, were compared among three BMI groups.</p><p><strong>Results: </strong>The basal levels of LH exhibited a significant reduction in overweight and obese women (p<0.001). Additionally, there was a significant decrease in the incidence of LH concentration exceeding 10 IU/L during controlled ovulation stimulation among overweight and obese women (7.19% vs 3.62% vs2.27%, p<0.05). Moreover, there were no significant differences observed among the three BMI groups regarding embryo transfer numbers, implantation, pregnancy or live birth rates.</p><p><strong>Conclusions: </strong>In obese women, clomiphene citrate effectively controlled LH levels, resulting a low prevalence of premature LH surge compared to patients with normal weight. This evidence contributes to a safer and more effective treatment for infertility in obese individuals.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1512821"},"PeriodicalIF":3.9,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of myo-inositol supplementation in mixed ovarian response IVF cohort: a systematic review and meta-analysis.","authors":"Jianeng Zhang, Huanhuan Zhang, Wenjing Zhou, Meiyan Jiang, Xianhua Lin","doi":"10.3389/fendo.2025.1520362","DOIUrl":"10.3389/fendo.2025.1520362","url":null,"abstract":"<p><strong>Objective: </strong>There has been substantial research conducted recently on the effect of myo-inositol (MI) on human reproduction. However, it still remains ambiguous about the therapeutic efficacy of MI in infertile women undergoing <i>in vitro</i> fertilization embryo transfer (IVF-ET). This systematic review and meta-analysis was carried out to investigate the efficacy of MI on IVF outcomes.</p><p><strong>Methods: </strong>Literatures were searched in the PubMed, Web of Science, Cochrane Library, ScienceDirect and Wanfang databases. The methodological quality was assessed using the Cochrane Risk of Bias tool. Data were pooled using a random- or fixed-effects model according to study heterogeneity. The results are expressed as odds ratio (OR) or mean difference (MD) with 95% confidence intervals (CIs). Heterogeneity was measured by the I² statistic. The protocol was prospectively registered with PROSPERO (CRD42024582149).</p><p><strong>Results: </strong>Eleven eligible studies with 981 participants reported the IVF outcomes of the MI group versus the control group. The synthesis results showed that the metaphase II (MII) oocyte rate was higher in the MI group than in the control group (OR 1.55, 95% CI 1.04-2.31, <i>P</i>=0.03). For polycystic ovary syndrome (PCOS) women, as well as non-obese PCOS women, a statistically significant improvement in MII oocyte rate were assumed after taking MI (OR 1.97, 95% CI 1.20-3.25, <i>P</i><0.01; OR 1.92, 95% CI 1.09-3.37, <i>P</i>=0.02) while there is no statistically significant advancement showed in the poor ovary responder (POR) women(OR 0.97, 95% CI 0.35-2.68, <i>P</i>=0.95). The fertilization rate was higher in the MI group than in the control group (OR 1.62, 95% CI 1.21-2.16, <i>P</i><0.01), for PCOS, non-obese PCOS and POR women (OR 1.59, 95% CI 1.16-2.18, <i>P</i><0.01; OR 1.87, 95% CI 1.52-2.31, <i>P</i><0.01; OR 2.42, 95% CI 1.48-3.95, <i>P</i><0.01).</p><p><strong>Conclusions: </strong>Our results suggest that MI supplementation improves the MII oocyte rate and the fertilization rate. More high-grade evidence from prospective randomized studies is warranted.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024582149.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1520362"},"PeriodicalIF":3.9,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glypican-4 trajectory predicts the risk of gestational diabetes mellitus and the requirement for insulin therapy during pregnancy.","authors":"Lei Tang, Ping Li, Ling Li","doi":"10.3389/fendo.2025.1483567","DOIUrl":"10.3389/fendo.2025.1483567","url":null,"abstract":"<p><strong>Background: </strong>Gestational diabetes mellitus (GDM), characterized by the onset of glucose intolerance during pregnancy, results in a series of complications for maternal and fetal health. Oral glucose tolerance test (OGTT) for screening glucose metabolism is performed in mid-to-late pregnancy, which remains less time to optimize glycemic control. Glypican-4, an insulin-sensitive adipose hormone, exhibits correlations with metabolic indicators. This study aims to investigate the association between glypican-4 and the risk of developing GDM, as well as the effects on insulin therapy and postpartum glucose metabolism.</p><p><strong>Methods: </strong>Based on pregnancy 75-g OGTT results, 718 subjects were grouped into normal glucose tolerance (NGT, n = 345) and GDM (n = 373) groups. 373 GDM patients were divided into the diet (n = 237) and insulin (n = 136) groups according to the treatment of hyperglycemia in pregnancy. Based on postpartum 75-g OGTT results, 158 of the 373 GDM patients were further divided into the NGT after delivery (NGTd, n = 138) and abnormal glucose tolerance (AGT, n = 20) groups.</p><p><strong>Results: </strong>Glypican-4 level was significantly higher in GDM than NGT subjects during pregnancy (<i>P</i>< 0.001). Glypican-4 was an independent predictor of GDM with the cut-offs were 0.40 ng/mL (5-12 weeks of gestation) and 0.79 ng/mL (13-23 weeks of gestation). Furthermore, glypican-4 level in the insulin group was higher than the diet group, which was a potential predictor of insulin therapy.</p><p><strong>Conclusions: </strong>Glypican-4 during pregnancy is associated with GDM risk, with higher levels indicating increased risk. Glypican-4 was also related to insulin therapy in GDM.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1483567"},"PeriodicalIF":3.9,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}